IQVIA vs Edwards Lifesciences
Side-by-side comparison of AI visibility scores, market position, and capabilities
World's largest CRO and healthcare data company; $15.2B FY2024 revenue; 1B+ patient records; powers pharma R&D and commercial analytics; benefits from GLP-1 and oncology pipeline boom.
About
IQVIA Holdings is the world's largest contract research organization (CRO) and leading provider of healthcare data and analytics, formed in 2016 through the $9 billion merger of IMS Health (healthcare information and technology services) and Quintiles Transnational Holdings (clinical research services), headquartered in Durham, North Carolina and trading on NYSE (IQV). The company generated approximately $15.2 billion in revenues for FY2024 under CEO Ari Bousbib, who led both legacy companies and has driven the combined entity to become an indispensable partner to pharmaceutical and biotechnology companies across the drug development lifecycle—from clinical trial design and execution through regulatory approval and commercial launch analytics.
Irvine CA structural heart devices (NYSE: EW) at $5.44B 2024 revenue; 60% TAVR global share, EVOQUE tricuspid +88% in Q4, Critical Care sold to BD for $4.2B, JenaValve acquisition expanding to aortic regurgitation.
About
Edwards Lifesciences Corporation is an Irvine, California-based structural heart disease and hemodynamic monitoring technology company — publicly traded on the New York Stock Exchange (NYSE: EW) as an S&P 500 Healthcare component — designing, developing, and manufacturing devices for heart valve replacement, transcatheter heart valve therapy, and cardiac critical care through approximately 15,800 employees in 100+ countries. In fiscal year 2024, Edwards reported total revenue of $5.44 billion (+8.6% year-over-year), driven by its dominant Transcatheter Aortic Valve Replacement (TAVR) franchise commanding approximately 60% global market share and 70%+ US market share. The Transcatheter Mitral and Tricuspid Therapies (TMTT) segment demonstrated exceptional growth, with Q4 TMTT revenue reaching $105 million (+88% year-over-year), as the EVOQUE tricuspid replacement system gained commercial momentum. In 2024, Edwards executed a major strategic transformation: divesting its Critical Care segment (hemodynamic monitoring) to Becton Dickinson for $4.2 billion — using the proceeds to fund two acquisitions: JenaValve Technology ($1.2B combined, expanding TAVR to high-risk patients with aortic regurgitation) and Endotronix. The company concentrates its entire focus on structural heart disease therapies.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.